Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria

Leena Gandhi*, Sai-Hong Ignatius Ou, Alice T. Shaw, Fabrice Barlesi, Anne-Marie C. Dingemans, Dong-Wan Kim, D. Ross Camidge, Brett G. M. Hughes, James C. -H. Yang, Javier de Castro, Lucio Crino, Herve Lena, Pascal Do, Sophie Golding, Walter Bordogna, Ali Zeaiter, Ahmed Kotb, Shirish Gadgeel

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalEuropean Journal of Cancer
Volume82
DOIs
Publication statusPublished - Sep 2017

Keywords

  • Alectinib
  • CNS metastases
  • NSCLC
  • RANO-HGG
  • RECIST
  • RESPONSE ASSESSMENT CRITERIA
  • BRAIN METASTASES
  • PSEUDOPROGRESSION
  • CHEMOTHERAPY
  • RADIATION
  • NECROSIS
  • DISEASE

Cite this